Leerink Remains Cautious on Ionis Pharmaceuticals (IONS) Following Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
May 27, 2016 6:23 AM EDTBMO Capital downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Market Perform with a price target of $26.00 (from $55.00).
Analyst Do Kim commented, "We are downgrading IONS shares to Market Perform from Outperform, following partner GSKs decision to delay the CARDIO-TTR Phase III... More
Needham & Company Cut PT, But Keeps 'Buy' on Ionis Pharmaceuticals (IONS) Amid Update
May 26, 2016 1:35 PM EDTNeedham & Company analyst Chad Messer is sticking with his Buy rating but reducing his target to $55 (from $88) on Ionis Pharmaceuticals (NASDAQ: IONS) after Ionis announced that partner GSK is delaying its decision to initiate that study until after NEURO-TTR reads out in 1H:17. Severe thrombocytopenia... More
Cowen Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
May 26, 2016 11:49 AM EDTCowen downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.
Shares of Ionis Pharmaceuticals closed at $35.26 yesterday.
... MoreAlnylam Pharma (ALNY) Gains on Ionis (IONS) Setback
May 26, 2016 11:33 AM EDTAlnylam Pharma (NASDAQ: ALNY) is gaining sharply Thursday (11.9%), related to a setback for Ionis Pharmaceuticals's (Nasdaq: IONS) IONIS-TTRRx program. Ionis' partner GSK has decided not to initiate a Phase 3 outcome study, CARDIO-TTR, which was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy. IONS is down 32%.
... MoreIonis Pharma (IONS): CARDIO-TTR Trial Uncertainty as GSK Stops Initiation - BMO
May 26, 2016 9:37 AM EDTBMO Capital Markets analyst, Do Kim, notes that Ionis Pharmaceuticals (NASDAQ: IONS) partner GSK will not initiate the CARDIO-TTR Phase III trial, following the FDA clinical hold related to patient safety monitoring in the study design. He believes that the study is probably... More
Ionis Pharma (IONS) Says Glaxo Will Not Initiate CARDIO-TTR Phase 3
May 26, 2016 7:35 AM EDTIonis Pharmaceuticals, Inc. (Nasdaq: IONS) provided an update on the IONIS-TTRRx program. Ionis is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy. Dr. Merrill Benson is also evaluating IONIS-TTRRx in an investigator-initiated Phase 2 open-label study in patients with TTR-related amyloid cardiomyopathy.
GSK, which has an option to exclusively license IONIS-TTRRx, has decided not to initiate a Phase 3 outcome study, CARDIO-TTR, which was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy. As announced in April 2016, the U.S. Food and Drug... More
